There have been significant economic benefits in Europe since the approval of the first biosimilar more than a decade ago. Although the first FDA biosimilar approval was in 2015, biosimilars are…
Market Outlook Xeljanz is the first-in-class JAK inhibitor approved for psoriatic arthritis (PsA); it is also the only oral targeted therapy approved for this indication besides Celgene’s PDE-4…
MARKET OUTLOOK Atopic dermatitis (AD) is a chronic inflammatory skin disease marked by pruritus, eczema, and, in some cases, disrupted sleep and poor quality of life. Topical agents (e.g.,…
Market Outlook The U.S. treatment landscape for osteoarthritic (OA) pain, despite being highly genericized, contains a large number of brand-only agents, including multiple opioid analgesics with…
Market Outlook The migraine prophylaxis market stands poised for disruption with the launch of Amgen/Novartis’s Aimovig (erenumab) in May 2018 and three additional anti-CGRP monoclonal…
MARKET OUTLOOK The introduction of additional Crohn’s disease (CD) agents has shifted—and will continue to shift—market dynamics. The newer non-TNF biologics (Takeda’s Entyvio and Janssen…
Dyslipidemia refers to abnormalities in lipids and lipoproteins in the circulation and is a key modifiable risk factor for cardiovascular (CV) disease. The most common lipid abnormalities include…
MARKET OUTLOOK The increasing rates of resistance to antibiotics among gram-negative pathogens have driven the development of antibiotics that target specific mechanisms of resistance and/or…
The triptan drug class dominates the market for approved prescription acute treatments for migraine. Despite the array of approved triptan options, most of them generic, new reformulations have…
MARKET OUTLOOK The ulcerative colitis (UC) market landscape is constantly evolving. The TNF-α inhibitors have the longest tenure among all biologics for UC; however, the launch of Takeda’s…
Dyslipidemia is a key modifiable risk factor for cardiovascular (CV) disease. Current lipid-modifying therapies, including statins, ezetimibe, fibrates, omega-3 fatty acid compounds, and the novel…
Market Outlook Despite the broad availability of antidepressants and atypical antipsychotics approved to treat major depressive disorder (MDD), approximately one-third of these patients are…
With the availability of multiple approved products for the treatment of diabetic macular edema (DME) in the EU5, including Bayer HealthCare’s Eylea, Novartis’s Lucentis, Allergan’s Ozurdex,…
MARKET OUTLOOK Progress in R&D and technology, regulatory and monetary incentives for advancing the development of treatments for rare diseases, and ongoing focus by the pharmaceutical market on…
Truxima (rituximab), Celltrion’s MabThera biosimilar, became the first oncology monoclonal antibody biosimilar to enter the European market in April 2017. Two months later, Sandoz’s Rixathon, a…